

# Vitamin D Insufficiency in Sunny Climates, Too

BY DIANA MAHONEY

BOSTON — The high prevalence of vitamin D deficiency found in a cohort of healthy children in a sunny Southwestern climate has prompted a call by the study's investigators for generalized routine screening of vitamin D levels among all children.

In a study designed to assess vitamin D levels in children living in a region with

year-round sunshine and to compare vitamin D levels in children with vague musculoskeletal pain with those of children without pain, Dr. Elizabeth A. Szalay and her colleagues at the University of New Mexico Hospital in Albuquerque retrospectively studied the serum 25-hydroxyvitamin D (25[OH]D) levels of 77 healthy children who were seen for musculoskeletal pain but who lacked a concrete diagnosis to explain their pain (pain

group). They also prospectively obtained serum 25(OH)D levels from 35 healthy children without pain.

The study included healthy children aged 2-16 years old who were freely ambulatory and could play outside as they chose. It excluded children with any endocrinopathy and those taking medications that affect vitamin D metabolism, Dr. Szalay said at the annual meeting of the Pediatric Orthopaedic Society of North America.

The study population (mean age, 9 years) included 66 girls and 46 boys, and was primarily Hispanic (59) and white (37). The average 25-hydroxyvitamin D levels for the pain and control groups were not statistically different, at 28 ng/mL and 31 ng/mL.

The mean 25(OH)D level was 29 ng/mL. "While there is no consensus on optimal serum vitamin D levels in children, optimal calcium absorption is seen

between 40 and 100 ng/mL," she said. "Vitamin D deficiency is defined by most experts as a [25-hydroxyvitamin D] level less than 20 ng/mL."

Collectively, only 13% of the children had vitamin D levels in the optimal range, while 33% had levels from 30 to 39 ng/mL, 35% had levels from 20 to 29 ng/mL, 16% had levels from 10 to 19 ng/mL, and 3% had levels less than 10 ng/mL—the level at which rachitic changes may occur.

The findings seem to suggest that modern lifestyles, even among children living in sun-rich regions, may be taking an ever greater toll on pediatric vitamin D levels and indirectly on pediatric bone health, said Dr. Szalay.

"Concern over hypovitaminosis D in children is warranted and routine screening should, at the very least, be considered," said Dr. Szalay, who reported having no conflicts of interest. ■

Combined administration of racemic citalopram (40 mg) and ketoconazole (200 mg), a potent CYP3A4 inhibitor, decreased the  $C_{max}$  and AUC of ketoconazole by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of citalopram. Ritonavir-Combined administration of a single dose of ritonavir (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and escitalopram (20 mg) did not affect the pharmacokinetics of either ritonavir or escitalopram. CYP3A4 and -2C19 Inhibitors-*In vitro* studies indicated that CYP3A4 and -2C19 are the primary enzymes involved in the metabolism of escitalopram. However, coadministration of escitalopram (20 mg) and ritonavir (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of escitalopram. Because escitalopram is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease escitalopram clearance. **Drugs Metabolized by Cytochrome P4502D6**-*In vitro* studies did not reveal an inhibitory effect of escitalopram on CYP2D6. In addition, steady state levels of racemic citalopram were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of citalopram, suggesting that coadministration, with escitalopram, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on escitalopram metabolism. However, there are limited *in vivo* data suggesting a modest CYP2D6 inhibitory effect for escitalopram, i.e., coadministration of escitalopram (20 mg/day for 21 days) with the tricyclic antidepressant desipramine (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in  $C_{max}$  and a 100% increase in AUC of desipramine. The clinical significance of this finding is unknown. Nevertheless, caution is indicated in the coadministration of escitalopram and drugs metabolized by CYP2D6. **Metoprolol**-Administration of 20 mg/day Lexapro for 21 days in healthy volunteers resulted in a 50% increase in  $C_{max}$  and 82% increase in AUC of the beta-adrenergic blocker metoprolol (given in a single dose of 100 mg). Increased metoprolol plasma levels have been associated with decreased cardioselectivity. Coadministration of Lexapro and metoprolol had no clinically significant effects on blood pressure or heart rate. **Electroconvulsive Therapy (ECT)**-There are no clinical studies of the combined use of ECT and escitalopram.

**USE IN SPECIFIC POPULATIONS: Pregnancy** Category C-In a rat embryo/fetal development study, oral administration of escitalopram (56, 112, or 150 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased fetal body weight and associated delays in ossification at the two higher doses (approximately 56 times the maximum recommended human dose [MRHD] of 20 mg/day on a body surface area [mg/m<sup>2</sup>] basis). Maternal toxicity (clinical signs and decreased body weight gain and food consumption), mild at 56 mg/kg/day, was present at all dose levels. The developmental no-effect dose of 56 mg/kg/day is approximately 28 times the MRHD on a mg/m<sup>2</sup> basis. No teratogenicity was observed at any of the doses tested (as high as 75 times the MRHD on a mg/m<sup>2</sup> basis). When female rats were treated with escitalopram (6, 12, 24, or 48 mg/kg/day) during pregnancy and through weaning, slightly increased offspring mortality and growth retardation were noted at 48 mg/kg/day which is approximately 24 times the MRHD on a mg/m<sup>2</sup> basis. Slight maternal toxicity (clinical signs and decreased body weight gain and food consumption) was seen at this dose. Slightly increased offspring mortality was also seen at 24 mg/kg/day. The no-effect dose was 12 mg/kg/day which is approximately 6 times the MRHD on a mg/m<sup>2</sup> basis. In animal reproduction studies, racemic citalopram has been shown to have adverse effects on embryo/fetal and postnatal development, including teratogenic effects, when administered at doses greater than human therapeutic doses. In two rat embryo/fetal development studies, oral administration of racemic citalopram (32, 56, or 112 mg/kg/day) to pregnant animals during the period of organogenesis resulted in decreased embryo/fetal growth and survival and an increased incidence of fetal abnormalities (including cardiovascular and skeletal defects) at the high dose. This dose was also associated with maternal toxicity (clinical signs, decreased body weight gain). The developmental no-effect dose was 56 mg/kg/day. In a rabbit study, no adverse effects on embryo/fetal development were observed at doses of racemic citalopram of up to 16 mg/kg/day. Thus, teratogenic effects of racemic citalopram were observed at a maternally toxic dose in the rat and were not observed in the rabbit. When female rats were treated with racemic citalopram (4.8, 12.8, or 32 mg/kg/day) from late gestation through weaning, increased offspring mortality during the first 4 days after birth and persistent offspring growth retardation were observed at the highest dose. The no-effect dose was 12.8 mg/kg/day. Similar effects on offspring mortality and growth were seen when dams were treated throughout gestation and early lactation at doses  $\geq$  24 mg/kg/day. A no-effect dose was not determined in that study. There are no adequate and well-controlled studies in pregnant women; therefore, escitalopram should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. **Pregnancy-Nonteratogenic Effects**-Neonates exposed to Lexapro or other SSRIs or SNRIs, late in the third trimester, have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. Such complications can arise immediately upon delivery. Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. These features are consistent with either a direct toxic effect of SSRIs and SNRIs or, possibly, a drug discontinuation syndrome. It should be noted that, in some cases, the clinical picture is consistent with serotonin syndrome [see *Warnings and Precautions*]. Infants exposed to SSRIs in late pregnancy may have an increased risk for persistent pulmonary hypertension of the newborn (PPHN). PPHN occurs in 1-2 per 1000 live births in the general population and is associated with substantial neonatal morbidity and mortality. In a retrospective, case-control study of 377 women whose infants were born with PPHN and 836 women whose infants were born healthy, the risk for developing PPHN was approximately six-fold higher for infants exposed to SSRIs after the 20th week of gestation compared to infants who had not been exposed to antidepressants during pregnancy. There is currently no corroborative evidence regarding the risk for PPHN following exposure to SSRIs in pregnancy; this is the first study that has investigated the potential risk. The study did not include enough cases with exposure to individual SSRIs to determine if all SSRIs posed similar levels of PPHN risk. When treating a pregnant woman with Lexapro during the third trimester, the physician should carefully consider both the potential risks and benefits of treatment [see *Dosage and Administration*]. Physicians should note that in a prospective longitudinal study of 201 women with a history of major depression who were euthymic at the beginning of pregnancy, women who discontinued antidepressant medication during pregnancy were more likely to experience a relapse of major depression than women who continued antidepressant medication. **Labor and Delivery**-The effect of Lexapro on labor and delivery in humans is unknown. **Nursing Mothers**-Escitalopram is excreted in human breast milk. Limited data from women taking 10-20 mg escitalopram showed that exclusively breast-fed infants receive approximately 3.9% of the maternal weight-adjusted dose of escitalopram and 1.7% of the maternal weight-adjusted dose of desmethylcitalopram. There were two reports of infants experiencing excessive somnolence, decreased feeding, and weight loss in association with breastfeeding from a racemic citalopram-treated mother; in one case, the infant was reported to recover completely upon discontinuation of racemic citalopram by its mother and, in the second case, no follow-up information was available. Caution should be exercised and breastfeeding infants should be observed for adverse reactions when Lexapro is administered to a nursing woman. **Pediatric Use**-Safety and effectiveness of Lexapro has not been established in pediatric patients (less than 12 years of age) with Major Depressive Disorder. Safety and effectiveness of Lexapro has been established in adolescents (12 to 17 years of age) for the treatment of major depressive disorder [see *Clinical Studies*]. Although maintenance efficacy in adolescent patients with Major Depressive Disorder has not been systematically evaluated, maintenance efficacy can be extrapolated from adult data along with comparisons of escitalopram pharmacokinetic parameters in adults and adolescent patients. Safety and effectiveness of Lexapro has not been established in pediatric patients less than 18 years of age with Generalized Anxiety Disorder. **Geriatric Use**-Approximately 6% of the 1144 patients receiving escitalopram in controlled trials of Lexapro in major depressive disorder and GAD were 60 years of age or older; elderly patients in these trials received daily doses of Lexapro between 10 and 20 mg. The number of elderly patients in these trials was insufficient to adequately assess for possible differential efficacy and safety measures on the basis of age. Nevertheless, greater sensitivity of some elderly individuals to effects of Lexapro cannot be ruled out. SSRIs and SNRIs, including Lexapro, have been associated with cases of clinically significant hyponatremia in elderly patients, who may be at greater risk for this adverse event [see *Hyponatremia*]. In two pharmacokinetic studies, escitalopram half-life was increased by approximately 50% in elderly subjects as compared to young subjects and  $C_{max}$  was unchanged [see *Clinical Pharmacology*]. 10 mg/day is the recommended dose for elderly patients [see *Dosage and Administration*]. Of 4422 patients in clinical studies of racemic citalopram, 1357 were 60 and over, 1034 were 65 and over, and 457 were 75 and over. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but again, greater sensitivity of some elderly individuals cannot be ruled out.

**DRUG ABUSE AND DEPENDENCE: Abuse and Dependence:** Physical and Psychological Dependence-Animal studies suggest that the abuse liability of racemic citalopram is low. Lexapro has not been systematically studied in humans for its potential for abuse, tolerance, or physical dependence. The premarketing clinical experience with Lexapro did not reveal any drug-seeking behavior. However, these observations were not systematic and it is not possible to predict on the basis of this limited experience the extent to which a CNS-active drug will be misused, diverted, and/or abused once marketed. Consequently, physicians should carefully evaluate Lexapro patients for history of drug abuse and follow such patients closely, observing them for signs of misuse or abuse (e.g., development of tolerance, increments of dose, drug-seeking behavior).

**OVERDOSAGE: Human Experience**-In clinical trials of escitalopram, there were reports of escitalopram overdose, including overdoses of up to 600 mg, with no associated fatalities. During the postmarketing evaluation of escitalopram, Lexapro overdoses involving overdoses of over 1000 mg have been reported. As with other SSRIs, a fatal outcome in a patient who has taken an overdose of escitalopram has been rarely reported. Symptoms most often accompanying escitalopram overdose, alone or in combination with other drugs and/or alcohol, included convulsions, coma, dizziness, hypotension, insomnia, nausea, vomiting, sinus tachycardia, somnolence, and ECG changes (including QT prolongation and very rare cases of torsade de pointes). Acute renal failure has been very rarely reported accompanying overdose. **Management of Overdose**-Establish and maintain an airway to ensure adequate ventilation and oxygenation. Gastric evacuation by lavage and use of activated charcoal should be considered. Careful observation and cardiac and vital sign monitoring are recommended, along with general symptomatic and supportive care. Due to the large volume of distribution of escitalopram, forced diuresis, dialysis, hemoperfusion, and exchange transfusion are unlikely to be of benefit. There are no specific antidotes for Lexapro. In managing overdose, consider the possibility of multiple-drug involvement. The physician should consider contacting a poison control center for additional information on the treatment of any overdose.

Forest Pharmaceuticals, Inc.  
Subsidiary of Forest Laboratories, Inc.  
St. Louis, MO 63045 USA  
Licensed from H. Lundbeck A/S

## Vertebroplasty Can Ease Pain Despite Fracture's Location

BY BRUCE JANCIN

COLORADO SPRINGS — Focal point tenderness on palpation over the fractured vertebral level is no longer a requirement for performing vertebroplasty, Dr. Benjamin A. Aronovitz said at the annual scientific conference of the Colorado Academy of Family Physicians.

"It used to be thought that pushing on the level of the fracture would tell you if vertebroplasty would help. Now we know that even if the pain is not at the level of the fracture, these procedures help," explained Dr. Aronovitz, president of the Colorado Radiological Society and a neuroradiologist who practices in Denver.

This about-face in the conventional wisdom was the result of a recent influential study by radiologists at the Mayo Clinic, Rochester, Minn. They reviewed the records of 534 consecutive patients who underwent vertebroplasty. Baseline focal point tenderness over subsequently treated fractures was present in 70% of the patients. Another 22% had focal point tenderness over the treated fractures plus subjective off-midline pain or tenderness upon palpation over nontreated vertebrae. And 8% of patients had no focal point tenderness at the level of the treated fractures, but had tenderness upon palpation elsewhere, either over nontreated vertebrae or subjective off-midline pain.

Patients with no baseline focal point tenderness over their treated fractures had significantly lower pain scores at rest at 1 month follow-up than the oth-

er two groups (Am. J. Neuroradiol. 2008;29:1622-6).

Dr. Aronovitz stressed that despite this development, the broad indication for vertebroplasty and kyphoplasty remains unchanged: pain relief in patients with painful acute or subacute vertebral compression fractures.

"If a fracture is not causing pain there's no reason to do these procedures. Medication and bed rest would work," he said.

A STIR (Short Tau Inversion Recovery) sequence MRI is the best indicator of the presence of a treatable vertebral compression fracture. Almost all patients will undergo this imaging procedure prior to vertebroplasty or kyphoplasty. Edema is often readily apparent on the MRI as long as 6-8 months after the fracture occurred—and that late edema is a strong indicator that the fracture is subacute and the patient will experience significant pain relief in response to the procedure.

"In our experience, 95% of treated patients get great pain relief. The best part of this procedure is these patients usually come in with terrible pain, and it's significantly reduced 2 hours post procedure," according to Dr. Aronovitz.

Referring physicians can write an order for vertebroplasty or kyphoplasty. Having done nearly 400 of them, Dr. Aronovitz is convinced the two procedures yield similar results. The bulk of the radiologic literature—as well as his personal experience—suggest that both procedures achieve roughly a 4-mm improvement in height per treated vertebra. ■



**'Even if the pain is not at the level of the fracture, these procedures help.'**

DR. ARONOVITZ